Vertex Pharmaceuticals executive Duncan McKechnie reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of Vertex common stock on February 13, 2026 at an indicated price of $487.76 per share to cover tax obligations. After this transaction, he directly owned 19,528 shares.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported a Form 4 tax-withholding disposition of 13,041 shares of common stock at $487.76 per share. After this transaction, she directly owns 133,487 Vertex shares.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of common stock at a price of $487.76 per share in a transaction coded "F," which represents payment of a tax liability by delivering shares, not an open-market sale. After this transaction, he directly owns 10,631 shares of Vertex common stock.
Vertex Pharmaceuticals executive reports tax-withholding share disposition. EVP and CMO Carmen Bozic disposed of 3,804 shares of Vertex Pharmaceuticals common stock on a tax-withholding basis at $487.76 per share. After this tax-withholding disposition, she directly holds 38,053 shares of Vertex common stock.
Vertex Pharmaceuticals executive Jonathan Biller reported two stock transactions. On February 13, 2026, he disposed of 2,993 shares of common stock at $487.76 per share to cover tax obligations and sold 988 shares in an open-market trade at $499.00 per share. After these transactions, he directly owned 16,838 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on February 24, 2025.
Vertex Pharmaceuticals director Sangeeta N. Bhatia reported an open-market sale of 266 shares of common stock at $500 per share. After this transaction, she directly owns 4,299 shares. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on 05/27/2025.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a tax-related share disposition. On February 13, 2026, he disposed of 1,903 shares of Vertex common stock at $487.76 per share as a tax-withholding disposition and now directly holds 20,143 shares of common stock.
Vertex Pharmaceuticals senior executive reports tax-related share disposition
Vertex Pharmaceuticals' SVP & Chief Accounting Officer Kristen Ambrose reported a Form 4 transaction involving a tax-withholding disposition of 1,393 shares of common stock at $487.76 per share on February 13, 2026. This type of transaction reflects shares withheld to cover tax obligations, rather than an open-market sale. After this transaction, Ambrose directly owns 8,734 shares of Vertex common stock.
Ourania Tatsis reported multiple secondary sales of common stock in filings relating to VRTX. The reported transactions list sales of 4,500 shares on 12/03/2025, 4,500 shares on 01/07/2026, 466 shares on 02/11/2026, 1,500 shares on 02/13/2026, and 609 shares on 02/17/2026. The excerpt also shows 368 shares associated with restricted stock vesting from the issuer on 02/17/2026.
Jonathan P. Biller reported sales of Common stock under Rule 144. The filing lists sales of 12/03/2025 ($155,803 for 347 shares), 02/11/2026 ($886,327.75 for 1,925 shares), 02/13/2026 ($493,012 for 988 shares) and 02/17/2026 ($1,211,902.96 for 2,476 shares).
The form also shows a Restricted Stock Vesting entry dated 02/17/2026 with a numeric reference of 1,244, listed under "Securities To Be Sold" with the method described as Compensation.